Related Experiment Video

Updated: Apr 7, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.8K

Beclabuvir for the treatment of hepatitis C

Ivan Gentile1, Emanuela Zappulo, Antonio Riccardo Buonomo

  • 1University of Naples 'Federico II,' Department of Clinical Medicine and Surgery , via S. Pansini 5, I-80131 Naples , Italy +39 0 81 7463178 ; +39 0 81 7463190 ; ivan.gentile@unina.it.

Expert Opinion on Investigational Drugs
|July 10, 2015
PubMed

Insights

Beclabuvir, a new direct-acting antiviral, shows a favorable profile for treating hepatitis C virus (HCV) infection. Its combination therapy achieves high viral eradication rates, offering a powerful option for HCV treatment.

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Hepatitis C virus (HCV) chronically infects 185 million people globally.
  • Current therapies reduce progression to advanced liver disease.
  • New direct-acting antivirals (DAAs) are emerging for HCV treatment.

Purpose of the Study:

  • This review examines beclabuvir, a novel non-nucleotide inhibitor of HCV polymerase.
  • The focus is on its pharmacokinetics, mechanism of action, safety, tolerability, and resistance profile.

Main Methods:

  • Review of beclabuvir's pharmacokinetic properties.
  • Analysis of its mechanism of action as an allosteric inhibitor.
  • Evaluation of safety, tolerability, and resistance patterns.

Main Results:

  • Beclabuvir demonstrates favorable pharmacokinetics, efficacy, and tolerability.
  • High viral eradication rates (~90%) observed with beclabuvir, asunaprevir, and daclatasvir combination therapy.
  • Effective against HCV genotype 1, the most prevalent worldwide.

Conclusions:

  • Beclabuvir possesses a highly favorable profile regarding pharmacokinetics, efficacy, tolerability, and resistance.
  • It is a potent therapeutic agent for HCV infection.
  • Beclabuvir is an optimal component in interferon-free combination therapies for HCV.
Abstract

Keywords:
BMS-791325IFN-free combinationsNS5B polymerase inhibitorsallostericantiviralsdirect-acting antiviral agenteradicationhepatitis C virus

More Related Videos

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection04:11

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

5.2K
A Protocol for Analyzing Hepatitis C Virus Replication13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.8K

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
46
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
32
Subviral Agents01:29

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
832
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.7K
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.4K
Retroviruses02:33

Retroviruses

Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
15.9K